Clinical Trial Detail

NCT ID NCT04140526
Title Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OncoImmune, Inc.
Indications

renal cell carcinoma

ovarian carcinoma

hepatocellular carcinoma

stomach carcinoma

Advanced Solid Tumor

sarcoma

colorectal cancer

lung non-small cell carcinoma

head and neck carcinoma

melanoma

Therapies

ONC-392

ONC-392 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.